Gossamer Bio (GOSS) news
Recent news
Gossamer Bio, - up to $100 mln additional funding upon FDA approval of Seralutinib
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development of seralutinib for the treatment of pulmonary arterial hypertension (PAH), has outlined potential financial implications tied to the regulatory approval of its lead candidate. The company plans…
AInvest Wire · Aug 21, 2026Gossamer Bio, - proceeds expected to fund operations into 2028
AInvest Wire · Aug 21, 2026Gossamer Bio, - $25 mln funded at initial closing, $125 mln upon FDA NDA acceptance
AInvest Wire · Aug 21, 2026Gossamer Bio announces up to $250 million structured private placement, including $150 million of committed capital, to fund Seralutinib through potential FDA approval
Gossamer Bio has announced a structured private placement financing of up to $250 million, including $150 million of committed capital, to advance the development of seralutinib for the treatment of pulmonary arterial hypertension (PAH) through potential U.S. FDA approval . The financing includes…
AInvest Wire · Aug 21, 2026Gossamer reacquires worldwide rights to Seralutinib
AInvest Wire · Jul 27, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.